These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF; J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol]. Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405 [TBL] [Abstract][Full Text] [Related]
7. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group. Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723 [TBL] [Abstract][Full Text] [Related]
8. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity]. Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624 [TBL] [Abstract][Full Text] [Related]
9. Treatment results of tonsillar lymphoma: a 10-year experience. Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316 [TBL] [Abstract][Full Text] [Related]
10. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck. Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
13. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155 [TBL] [Abstract][Full Text] [Related]
14. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536 [TBL] [Abstract][Full Text] [Related]
15. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737 [TBL] [Abstract][Full Text] [Related]
17. Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach. De Sanctis V; Martelli M; Anticoli AP; Caronna R; Chirletti P; Giovannini M; Santarelli M; Enrici RM; Mandelli F Anticancer Res; 2001; 21(6A):4169-72. PubMed ID: 11911313 [TBL] [Abstract][Full Text] [Related]
18. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx]. Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649 [TBL] [Abstract][Full Text] [Related]
19. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281 [TBL] [Abstract][Full Text] [Related]
20. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy]. Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]